DULOXETINE HYDROCHLORIDE capsule, delayed release

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

现在购买

下载 资料单张 (PIL)
16-05-2016
下载 产品特点 (SPC)
16-05-2016

有效成分:

DULOXETINE HYDROCHLORIDE (UNII: 9044SC542W) (DULOXETINE - UNII:O5TNM5N07U)

可用日期:

NCS HealthCare of KY, Inc dba Vangard Labs

INN(国际名称):

DULOXETINE HYDROCHLORIDE

组成:

DULOXETINE 30 mg

给药途径:

ORAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Duloxetine delayed-release capsules, USP are indicated for the treatment of: - Major Depressive Disorder [see Clinical Studies (14.1)] - Generalized Anxiety Disorder [see Clinical Studies (14.2)] - Diabetic Peripheral Neuropathy [see Clinical Studies (14.3)] - Chronic Musculoskeletal Pain [see Clinical Studies (14.5)] Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. The use of duloxetine delayed-release capsules within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.8) and Warnings and Precautions (5.4)]. Starting duloxetine delayed-release capsules in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of sero

產品總結:

Duloxetine Delayed-Release Capsules, USP are supplied as: 20 mg capsules: Hard gelatin capsule with a green opaque body and green opaque cap. Imprinted “APO D20” in black ink. Filled with white to off-white granules. 30 mg capsules : Hard gelatin capsule with a white opaque body and blue opaque cap. Imprinted “APO D30” in green ink. Filled with white to off-white granules.  Blistercards of 30 (NDC 0615-8034-39) 60 mg capsules : Hard gelatin capsules with a green opaque body and blue opaque cap. Imprinted “APO D60” in white ink. Filled with white to off-white granules.  Blistercards of 30 (NDC 0615-8035-39) Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

授权状态:

Abbreviated New Drug Application

资料单张

                                DULOXETINE HYDROCHLORIDE- DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED
RELEASE
NCS HealthCare of KY, Inc dba Vangard Labs
----------
Medication Guide
Duloxetine Delayed-Release Capsules, USP
(doo-LOX-e-teen)
Read this Medication Guide before you start taking duloxetine
delayed-release capsules and each time
you get a refill. There may be new information. This information does
not take the place of talking to
your healthcare provider about your medical condition or treatment.
Talk to your healthcare provider about:
•
all risks and benefits of treatment with antidepressant medicines
•
all treatment choices for depression or other serious mental illness
What is the most important information I should know about
antidepressant medicines, depression, other
serious mental illnesses, and suicidal thoughts or actions?
1. Duloxetine delayed-release capsules and other antidepressant
medicines may increase suicidal thoughts
or actions in some children, teenagers, or young adults within the
first few months of treatment or when
the dose is changed.
2. Depression and other serious mental illnesses are the most
important causes of suicidal thoughts or
actions. Some people may have a particularly high risk of having
suicidal thoughts or actions. These
include people who have (or have a family history of) bipolar illness
(also called manic-depressive
illness).
3. How can I watch for and try to prevent suicidal thoughts and
actions?
•
Pay close attention to any changes in mood, behavior, actions,
thoughts, or feelings, especially
sudden changes. This is very important when an antidepressant medicine
is started or when the
dose is changed.
•
Call your healthcare provider right away to report new or sudden
changes in mood, behavior,
thoughts, or feelings.
•
Keep all follow-up visits with your healthcare provider as scheduled.
Call your healthcare
provider between visits as needed, especially if you have concerns
about symptoms.
Call your healthcare provider right away if you have any of the
following symptoms or feelings,
es
                                
                                阅读完整的文件
                                
                            

产品特点

                                DULOXETINE HYDROCHLORIDE- DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED
RELEASE
NCS HEALTHCARE OF KY, INC DBA VANGARD LABS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
DULOXETINE DELAYED-RELEASE CAPSULES, USP
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
DULOXETINE DELAYED-RELEASE CAPSULES, USP.
DULOXETINE DELAYED-RELEASE CAPSULES, USP FOR ORAL USE.
INITIAL U.S. APPROVAL: 2004
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_.
INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN,
ADOLESCENTS, AND YOUNG ADULTS TAKING
ANTIDEPRESSANTS (5.1)
MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS
(5.1)
RECENT MAJOR CHANGES
Boxed Warning: Suicidal Thoughts and Behaviors 10/2014
Indications and Usage (1) 10/2014
Dosage and Administration: Dosage for Treatment of Generalized Anxiety
Disorder (2.2) 10/2014
Contraindications:
Uncontrolled Narrow-Angle Glaucoma (4.2) Removed 07/2014
Warnings and Precautions:
Orthostatic Hypotension, Falls and Syncope (5.3) 11/2014
Angle-Closure Glaucoma (5.9) 07/2014
INDICATIONS AND USAGE
Duloxetine delayed-release capsules, USP are a serotonin and
norepinephrine reuptake inhibitor (SNRI) indicated for: (1)
Major Depressive Disorder (MDD) (1)
Generalized Anxiety Disorder (GAD) (1)
Diabetic Peripheral Neuropathic Pain (DPNP) (1)
Chronic Musculoskeletal Pain (1)
DOSAGE AND ADMINISTRATION
Take duloxetine once daily, with or without food. Swallow duloxetine
whole; do not crush or chew, do not open capsule.
Take a missed dose as soon as it is remembered. Do not take two doses
of duloxetine at the same time. (2)
INDICATION
STARTING DOSE
TARGET DOSE
MAXIMUM DOSE
MDD (2.1)
40 mg/day to 60 mg/day
Acute Treatment: 40 mg/day (20
mg twice daily) to 60 mg/day
(once daily or as 30 mg twice
daily);
Maintenance Treatment: 60
mg/day
120 mg/day
GAD (2.2)
60 mg/day
60 mg/day (once daily)
120 mg/day
DPNP (2.3)
60 mg/day
60 mg/day (once daily)
60 mg/day
Ch
                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报